Influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection

Objective: To study the influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection. Methods: A total of 118 children with recurrent respiratory tract infection who were treated in the hospital between January 2015 and January 2017 were collected and divided into control group and observation group by random number table method, 59 cases in each group. Control group received conventional therapy, and observation group received pidotimod combined with conventional therapy. The differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were compared between the two groups before and after treatment. Results: Before treatment, the differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were not statistically significant between the two groups. after 1 week of treatment, serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of both groups of children were lower than those before treatment while IFN-γ contents as well as IFN-γ/ IL-4 levels were higher than those before treatment, and serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of observation group were lower than those of control group while IFN-γ content as well as IFN-γ/ IL-4 level was higher than those of control group. Conclusion: Pidotimod combined with conventional drug therapy can effectively inhibit the infection status and optimize the Th1/Th2 cellular immune function of children with recurrent respiratory tract infection.

Stimulation of Phagocytosis and Production of Antibodies against Canine Herpesvirus Type 1 by Pidotimod (Adimod^TM)

Neutrophils are the most important circulating phagocytes. Circulating mono-cytes and precursors of tissue macrophages also have the ability to phagocytize. Pidotimod (ADIMODTM) exerts immunostimulatory and immunoregulatory effects through the stimulation and regulation of cellular immune responses by lymphocytes Canine herpesvirus (CHV) mainly affect puppies between the first and second weeks of age, causing high morbidity in the litter. To date, there is only one commercial vaccine in Europe to prevent disease. In this work, inactivated CHV cultures were inoculated in rabbits, adsorbed and not adsorbed to chitosan nanoparticles. Phagocytosis in the presence or absence of specific antibodies was measured. Response of virus neutralizing antibodies was also evaluated. AdimodTM enhanced the nonspecific and specific phagocytotic response. The association of the virus to the nanoparticles increased the phagocytic ability of blood cells;however, AdimodTM alone had a greater effect on phagocytic activity and generated a stronger immune response that corresponded to the increased phagocytosis (p TM was used.

Clinical observation of effects of pidotimod combined with ribavirin on inflammatory factors, T lymphocyte subsets, immunoglobulin and blood biochemical markers in children with hand-foot-mouth disease

Objective:To observe the effects of pidotimod combined with ribavirin on inflammatory factors, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in children with hand-foot-mouth disease.Methods: A total of 108 children with foot-hand-and-mouth epidemic in our hospital from Jan. 2013-Dec. 2016 were divide into the observation group and the control group, each groups has 54 cases. Two groups of children were treated with isolation, the observation group was given pidotimod combined with ribavirin, and the control group was treated with ribavirin. 5 mL venous blood of two group patients were collected at admission and after 6 d treatment, respectively, to compare inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin in two groups.Results: Before treatment, the levels of inflammatory factor, T lymphocyte subsets, immunoglobulin, lactate, D-dimer and procalcitonin of two groups were not statistically significant. Compared with groups after treatment, the levels of CRP, IL-6, TNF-α were lower than that before treatment, CRP (2.23±0.37) mg/L, IL-6 (21.24±9.81) pg/mL and TNF-α (56.97±50.36) pg/mL levels in observation group after treatment were significantly lower than those in control group, the difference was statistically significant. After treatment, the levels of CD3, CD4, CD4/CD8, IgG, IgA and IgM in control group were significantly higher than that before treatment, the difference was statistically significant;After treatment, the levels of CD3 (51.26±10.27)%, CD4 (36.36±4.09)% and CD4/CD8 (1.60±0.47), IgG (10.24±1.82) mg/L, IgA (1.30±0.31) mg/L and IgM (1.48±0.30) mg/L in observation group were significantly higher than in control group, the difference was statistically significant. After treatment, the levels of lactate, D-dimer and procalcitonin in two groups were significantly lower than that before treatment, the difference was statistically significant;After treatment, the levels of lactate (1.19±0.20) mmol/L, D-dimer (150.23±27.21) ng/mL, and procalcitonin (0.08±0.02) ng/mL in observation group were significantly higher than in control group, the difference was statistically significant. Conclusion: Pidotimod combined with ribavirin has a pronounced effect on children with hand-foot-mouth disease, which can effectively reduce the body's inflammatory response, enhance immune function, improve clinical biochemical indicators, and should be widely recommended for clinical use.

Application analysis of pidotimod in the treatment of allergic rhinitis in children accompanied by allergic asthma

Objective:To observe the application effect of pidotimod in the treatment of allergic rhinitis in children accompanied by allergic asthma.Methods:A total of 60 children with allergic rhinitis accompanied by allergic asthma who were admitted in our hospital from January, 2013 to January, 2015 were included in the study and randomized into the treatment group and the control group with 30 cases in each group. The patients in the two groups were given routine treatments in combined with sublingual immunotherapy. On this basis, the patients in the treatment group were given additional pidotimod. The immunological function, inflammatory cytokine level, and pulmonary function improvement in the two groups were observed. Results:The immunological function, inflammatory cytokine level, and pulmonary function improvement in the treatment group were significantly superior to those in the control group. Conclusions:Pidotimod can significantly enhance the immunological function in children with allergic rhinitis in children accompanied by allergic asthma, alleviate the inflammatory reaction, and promote the pulmonary function improvement, with an accurate efficacy.

Effects of montelukast sodium combined with pidotimod on acute phase protein and immune function in children with acute bronchitis

Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases children with acute bronchitis acted as research objects were randomly divided into control group (n=65) and observation group (n=63). On the basis of conventional therapy, control group was treated by plus pidotimod. On this base, observation group was treated with montelukast sodium. The changes of acute phase proteins (CRP, HP, a1-AAG and CER) and immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) levels before and after treatment were observed after 2 months. Results: Before treatment, CRP, HP, a1-AAG, CER, CD3+, CD4+, CD8+ and CD4+/CD8+ levels of two groups had no statistically significant difference;CRP, HP, a1-AAG, CER, and CD8+ levels of control and observation groups decreased significantly after treatment, the decreases of observation group were more obvious than that of control group, and the levels after treatment were significantly lower than that of control groups. The levels of CD3+, CD4+ and CD4+/CD8+ in two groups after treatment were significantly higher than those before treatment. For observation group, the levels of CD3+, CD4+ and CD4+/CD8+ increased more significantly after treatment, which were significantly higher than that of the control group. Conclusion: Using Montelukast sodium combined with pidotimod can effectively reduce the children's acute phase protein levels, improve immune function, which has clinical value for the treatment of children with acute bronchitis.

Exploration of Therapeutic Measures and Clinical Efficacy for Recurrent Respiratory Infections in Children

Objective:To explore the treatment strategies and clinical effects for recurrent respiratory infections in children.Methods:From May 2022 to May 2024,100 pediatric patients with recurrent respiratory infections were selected in this study and evenly divided into two groups.The control group(50 patients)was treated with conventional therapy supplemented with budesonide,while the observation group(50 patients)received pidotimod treatment in addition to the control group’s treatment.Subsequently,the duration of clinical symptom improvement,respiratory function enhancement,serological index changes,reinfection status,and parental satisfaction were compared between the two groups.Results:In terms of clinical symptoms,the observation group showed significantly shorter durations of fever reduction,cough relief,tonsil swelling reduction,and disappearance of fine wet rales compared to the control group(average reduction times were 1.6 days,2.3 days,2.1 days,and 1.9 days,respectively,P<0.05).Regarding respiratory function,the observation group experienced a 12%increase in peak expiratory flow rate variability,a 0.6-liter increase in lung capacity,a 0.7-liter increase in forced lung capacity,and a 0.5-liter increase in forced expiratory volume in the first second after treatment,all significantly higher than the control group(P<0.05).Serological testing revealed that interferon-γand interleukin-2 levels increased by 15%and 18%,respectively,while interferon-α,interleukin-5,and interleukin-4 levels decreased by 10%,12%,and 9%,respectively,in the observation group,showing significant differences compared to the control group(P<0.05).Additionally,the reinfection rate in the observation group(10%)was significantly lower than that in the control group(30%),with an average reduction of two reinfections within one year and a 3.2-day shorter infection control time(P<0.05).In terms of parental satisfaction,the observation group achieved 95%,significantly higher than the 70%in the control group(P<0.05).Conclusion:The addition of pidotimod to conventional therapy for pediatric patients with recurrent respiratory infections can significantly alleviate clinical symptoms,promote the recovery of respiratory function,regulate serological indicators,effectively reduce the risk of reinfection,and improve parental satisfaction.This method deserves widespread clinical application.

匹多莫德对支原体感染小鼠肺功能损伤的影响及其机制研究

目的观察匹多莫德对支原体感染(MPI)小鼠肺功能损伤的保护作用,并探讨其可能机制。方法MPI小鼠随机分为MPI组和实验A、B、C组,每组10只;另取10只健康小鼠设为正常组。实验A、B、C组分别灌胃匹多莫德颗粒100、200和400 mg/kg,正常组、MPI组灌胃等量生理盐水,1次/d,持续3 d。采用小动物呼吸机检测肺功能,紫外分光光度法和细胞色素C还原法检测血清氧化应激指标,酶联免疫吸附试验检测血清免疫指标,苏木精-伊红染色观察肺组织病理变化,Western blotting检测肺组织核因子E2相关因子2(Nrf2)、血红素加氧酶-1(HO-1)蛋白表达。结果与正常组比较,MPI组每分钟通气量(MV)、潮气量(TV)、最大呼气量(MEV)均减少(P<0.05),血清谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)活性、γ干扰素(IFN-γ)水平均降低(P<0.05),血清白细胞介素-4(IL-4)水平升高(P<0.05);与MPI组比较,实验A、B、C组MV、TV、MEV均增加(P<0.05),GSH-Px、SOD活性均增强(P<0.05),IFN-γ水平升高(P<0.05),IL-4水平降低(P<0.05);与实验A组比较,实验B、C组MV、TV、MEV均增加(P<0.05),GSH-Px、SOD活性均增强(P<0.05),IFN-γ水平升高(P<0.05),IL-4水平降低(P<0.05);与实验B组比较,实验C组MV、TV、MEV均增加(P<0.05),GSH-Px、SOD活性均增强(P<0.05),IFN-γ水平升高(P<0.05),IL-4水平降低(P<0.05)。与正常组比较,MPI组肺组织Nrf2、HO-1蛋白相对表达量均降低(P<0.05);与MPI组比较,实验A、B、C组肺组织Nrf2、HO-1蛋白相对表达量均升高(P<0.05);与实验A组比较,实验B、C组肺组织Nrf2、HO-1蛋白相对表达量均升高(P<0.05);与实验B组比较,实验C组肺组织Nrf2、HO-1蛋白相对表达量均升高(P<0.05)。结论匹多莫德可能通过调节Nrf2/HO-1信号通路,改善MPI小鼠肺功能和免疫功能,减轻氧化应激损伤。

匹多莫德治疗小儿呼吸系统反复感染的临床效果

目的探讨匹多莫德治疗小儿呼吸系统反复感染的临床效果。方法选取2022年1月至12月安丘市人民医院治疗的96例呼吸系统反复感染患儿作为研究对象,按照随机数字表法分为对照组和观察组,每组各48例。对照组采用美洛西林钠联合布地奈德治疗,观察组在对照组基础上采用匹多莫德治疗。比较两组炎症因子水平、免疫球蛋白水平、临床症状消失时间、肺功能、临床疗效、不良反应发生情况和再次感染情况。结果治疗后,观察组γ干扰素、白细胞介素-2水平高于对照组,肿瘤坏死因子-α、白细胞介素-4水平低于对照组(P<0.05);观察组各项临床症状消失时间均短于对照组(P<0.05);观察组免疫球蛋白A、免疫球蛋白G、免疫球蛋白M水平均高于对照组(P<0.05);观察组第1秒用力呼气容积、用力肺活量、最高呼气流速变异率、一秒率水平均高于对照组(P<0.05);观察组临床总有效率高于对照组(P<0.05);观察组不良反应总发生率低于对照组(P<0.05);观察组再次感染次数少于对照组,再感染持续时间短于对照组(P<0.05)。结论匹多莫德治疗小儿呼吸系统反复感染的临床效果较好,值得推广。

喉咽清口服液、匹多莫德联合阿莫西林克拉维酸钾治疗儿童急性化脓性扁桃体炎的临床疗效

目的 观察喉咽清口服液、匹多莫德联合阿莫西林克拉维酸钾治疗儿童急性化脓性扁桃体炎的临床疗效及其对炎性反应、免疫功能的影响。方法 选取2020年11月—2021年9月淄博市妇幼保健院收治的急性化脓性扁桃体炎患儿60例作为研究对象,采用随机数字表法分为对照组与观察组,各30例。对照组采用阿莫西林克拉维酸钾与匹多莫德治疗,观察组在对照组基础上加服喉咽清口服液治疗,2组疗程均为7 d。比较2组临床疗效、发热消退时间、咽痛消失时间、吞咽困难消失时间及治疗前、治疗7 d后实验室指标(白细胞计数、C反应蛋白、降钙素原、白介素-2、白介素-6、CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)),并观察2组不良反应发生情况。结果 观察组总有效率为96.67%,高于对照组的80.00%(χ^(2)=4.043,P=0.044)。观察组发热消退时间、咽痛消失时间、吞咽困难消失时间短于对照组(P<0.01)。治疗7 d后,2组白细胞计数少于治疗前,C反应蛋白、降钙素原、白介素-2、白介素-6低于治疗前,CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)高于治疗前,且观察组各指标优于对照组(P<0.01)。2组均未出现严重不良反应。结论 喉咽清口服液、匹多莫德联合阿莫西林克拉维酸钾治疗儿童急性化脓性扁桃体炎的疗效确切,能够有效改善患儿细胞免疫功能及减轻炎性反应,进而缓解症状,促进疾病快速康复,且安全性较高。

补中益气汤对结直肠癌术后化疗脾胃气虚患者免疫功能的影响

目的探讨补中益气汤对结直肠癌术后化疗脾胃气虚患者免疫功能的影响。方法选取2022年2月至2023年5月收治的90例结直肠癌患者作为研究对象,按照其治疗方式分为对照组、匹多莫德组、补中益气汤组,各30例,分别采用化疗治疗、化疗+匹多莫德治疗、化疗+补中益气汤治疗,比较3组患者治疗疗效、免疫功能指标、不良反应发生率等。结果补中益气组治疗疗效90%高于匹多莫德组63.33%、对照组33.33%,匹多莫德组治疗疗效63.33%高于对照组33.33%(P<0.05);治疗前组间免疫功能指标比较差异无统计学意义,P>0.05,治疗后,补中益气汤组CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)、NK细胞高于匹多莫德组、对照组,CD_(8)^(+)低于匹多莫德组、对照组(P<0.05),匹多莫德组CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)、NK细胞高于对照组,CD_(8)^(+)低于对照组(P<0.05);补中益气组不良反应发生率6.67%低于匹多莫德组30.00%、对照组33.33%(P<0.05),匹多莫德组30.00%低于对照组33.33%(P>0.05)。结论结直肠癌术后化疗患者再接受补中益气汤治疗,能更好的调控机体免疫功能,改善疾病证候症状,进而提升疗效。

匹多莫德辅助化疗对肺结核大鼠外周血T淋巴细胞亚群的影响及其机制探讨

目的 探究匹多莫德辅助化疗对肺结核大鼠外周血T淋巴细胞亚群的影响及其作用机制。方法 从65只大鼠中随机选取15只作为对照组,其余大鼠复制肺结核模型,随机分为模型组,化疗组及联合治疗组,每组15只。化疗组给予异烟肼50 mg/kg,利福霉素SV钠50 mg/kg,联合治疗组在化疗组基础上给予匹多莫德200 mg/kg,对照组、模型组给予等量生理盐水。连续治疗8周后,比较大鼠外周血CD3^(+)、CD4^(+)、CD8^(+),胸腺指数及血清IgG水平,肺组织Toll样受体4(TLR4)、核转录因子κB(NF-κB)、髓样细胞分化因子88(MyD88)蛋白表达。结果 与对照组比较,模型组、化疗组CD3+、CD4+,胸腺指数和IgG水平均降低(P <0.05),CD8^(+)和TLR4、MyD88、NF-κB蛋白相对表达量均升高(P <0.05);与模型组比较,化疗组及联合治疗组CD3^(+)、CD4^(+)、胸腺指数和IgG水平均升高(P <0.05),CD8^(+)和TLR4、MyD88、NF-κB蛋白相对表达量均降低(P <0.05);与化疗组比较,联合治疗组CD3^(+)、CD4^(+)、胸腺指数和IgG水平均升高(P <0.05),CD8^(+),TLR4、MyD88、NF-κB蛋白相对表达量均降低(P <0.05)。结论 匹多莫德辅助化疗能够提高肺结核大鼠免疫功能,其作用机制可能与TLR/NF-κB信号通路有关。

匹多莫德联合丙酸氟替卡松治疗儿童哮喘临床观察

目的探讨匹多莫德联合丙酸氟替卡松治疗儿童哮喘的临床疗效。方法选取医院2021年7月至2022年6月收治的哮喘患儿102例,随机分为对照组和观察组,各51例。两组患儿均予对症支持治疗,并予吸入丙酸氟替卡松,观察组患者加用匹多莫德片。两组均持续治疗2个月。结果观察组患儿临床总有效率为94.12%,显著高于对照组的78.43%(P<0.05)。观察组患儿治疗后的肺活量、第1秒用力呼气容积、呼气峰流速均显著高于对照组,免疫球蛋白IgA,IgG,IgM水平及T淋巴细胞CD_(4)^(+)和CD_(4)^(+)/CD_(8)^(+)均显著低于对照组,T淋巴细胞CD_(8)^(+)水平显著高于对照组(P<0.05)。结论匹多莫德联合丙酸氟替卡松治疗儿童哮喘,能显著提高临床疗效,改善患儿的肺功能,提高免疫球蛋白及T淋巴细胞水平。

匹多莫德联合常规疗法在哮喘-慢阻肺重叠综合征中的有效性及安全性分析

目的分析对哮喘-慢性阻塞性肺疾病(慢阻肺)重叠综合征患者实施匹多莫德联合常规疗法(沙美特罗+氨溴索+噻托溴铵)治疗的安全性以及有效性。方法52例哮喘-慢阻肺重叠综合征患者,根据治疗方式不同分为联合治疗组和基础治疗组,每组26例。基础治疗组选择基础治疗,联合治疗组在基础治疗组的基础上采用匹多莫德联合常规疗法(沙美特罗+氨溴索+噻托溴铵)实施治疗。比较两组患者不良反应发生率、治疗效果及治疗前后的肺功能指标[第1秒用力呼气容积(FEV1)/用力肺活量(FVC)、FEV1]、肿瘤坏死因子-α(TNF-α)、淋巴细胞百分比。结果联合治疗组患者不良反应发生率3.85%低于基础治疗组的23.08%,差异具有统计学意义(P<0.05)。联合治疗组患者治疗总有效率96.15%高于基础治疗组的69.23%,差异具有统计学意义(P<0.05)。治疗后,两组患者FEV1/FVC、FEV1水平均高于治疗前,且联合治疗组患者FEV1/FVC(70.21±6.38)%、FEV1(1.62±0.19)L均高于基础治疗组的(59.07±6.11)%、(1.36±0.21)L,差异均具有统计学意义(P<0.05)。治疗后,两组患者TNF-α、淋巴细胞百分比均低于治疗前,且联合治疗组患者TNF-α(27.87±2.31)μg/L、淋巴细胞百分比(35.42±3.27)%均低于基础治疗组的(34.15±3.49)μg/L、(40.01±3.34)%,差异均具有统计学意义(P<0.05)。结论对哮喘-慢阻肺重叠综合征患者实施匹多莫德联合常规疗法(沙美特罗+氨溴索+噻托溴铵)治疗,在提升治疗效果的同时还能使患者的肺功能指标、TNF-α以及淋巴细胞百分比等指标得到改善,并且不良反应比较轻微,具有较高的安全性以及应用价值,值得推广。

孟鲁司特钠联合匹多莫德治疗反复呼吸道感染患儿的效果

目的:观察孟鲁司特钠联合匹多莫德治疗反复呼吸道感染患儿的效果。方法:选取2019年5月至2021年5月该院收治的70例反复呼吸道感染患儿进行前瞻性研究,按随机数字表法将其分为对照组和观察组各35例。对照组采用匹多莫德口服液治疗,观察组在对照组基础上联合孟鲁司特钠咀嚼片治疗,比较两组临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC]水平、免疫功能指标[免疫球蛋白A(IgA)、免疫球蛋白E(IgE)、免疫球蛋白G(IgG)]水平、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)]水平和不良反应发生率。结果:观察组治疗总有效率为91.43%(32/35),高于对照组的54.15%(20/35),差异有统计学意义(P<0.05);治疗后,两组FVC、FEV_(1)、FEV_(1)/FVC水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组IgA、IgG水平均高于治疗前,且观察组高于对照组,两组IgE水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组TNF-α、IL-8水平均低于治疗前,且观察组低于对照组,两组IL-10水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合匹多莫德治疗反复呼吸道感染患儿可提高治疗总有效率和肺功能指标水平,改善免疫功能指标和炎性因子水平,其效果优于单纯匹多莫德治疗。

注射用复方三维B(Ⅱ)联合匹多莫德分散片治疗带状疱疹神经痛的临床效果及安全性评价

目的探讨注射用复方三维B(Ⅱ)联合匹多莫德分散片治疗带状疱疹神经痛的临床效果。方法回顾性分析2020年5月—2021年9月期间就诊于吉林大学第二医院的胸段带状疱疹后神经痛患者128例的临床资料,按照随机数表法将其分为观察组和对照组,每组64例,对照组患者仅采用匹多莫德分散片进行治疗,观察组则采取注射用复方三维B(Ⅱ)联合匹多莫德分散片治疗方案。对比两组患者的治疗效果及不良反应。结果治疗后1 d、7 d、1个月以及3个月观察组患者的VAS评分均比对照组低,差异有统计学意义(P<0.05)。观察组治疗有效率为98.44%,明显高于对照组的87.50%,差异有统计学意义(χ^(2)=4.303,P<0.05)。治疗后观察组患者的烧灼感、瘙痒感评分低于对照组,差异有统计学意义(P<0.05)。结论注射用复方三维B(Ⅱ)联合匹多莫德分散片治疗方案可有效改善胸段带状疱疹后神经痛患者的疼痛程度,缓解临床症状,提升治疗有效率。

匹多莫德联合肠内营养对ICU肺炎患者免疫功能、正五聚体蛋白-3水平及临床效果的影响

目的:探讨匹多莫德联合肠内营养对重症监护室(ICU)肺炎患者免疫功能、正五聚体蛋白-3(PTX3)水平及临床效果的影响。方法:选取2019年3月─2021年3月在福州市第一医院呼吸科治疗的110例ICU肺炎患者为研究对象,按照随机数表法将其分为对照组和研究组,各55例。对照组采用肠内营养干预,研究组在对照组基础上联合匹多莫德。观察两组临床疗效、临床一般指标、免疫功能及PTX3水平。结果:研究组临床总有效率高于对照组,差异有统计学意义(P<0.05)。研究组退热时间、咳嗽消失时间早于对照组,ICU入住时间及住院时间均短于对照组,差异有统计学意义(P<0.001)。两组治疗前CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、C反应蛋白(CRP)、PTX3比较,差异无统计学意义(P>0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、IgA、IgM及IgG均升高,CD8^(+)、CRP、PTX3降低,且研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、IgA、IgM、IgG高于对照组,CD8^(+)、CRP、PTX3低于对照组,差异有统计学意义(P<0.05)。结论:ICU肺炎患者采用匹多莫德联合肠内营养治疗临床效果更佳,可显著提高机体免疫功能,降低PTX3水平。

匹多莫德联合沙美特罗替卡松对小儿支气管哮喘血气分析指标及T淋巴细胞亚群的影响

目的观察匹多莫德与沙美特罗替卡松联合治疗对小儿支气管哮喘血气分析指标及T淋巴细胞亚群的影响。方法选取开封市儿童医院收治的94例支气管哮喘患儿为研究对象(2021年1月至2023年1月),依据随机抽签法分为参照组(47例)、试验组(47例)。参照组采用沙美特罗替卡松治疗,试验组在参照组基础上增加匹多莫德治疗。比较两组治疗后临床总有效率,第1秒用力呼气容积(FEV_(1)),氧分压(PaO_(2)),用力肺活量(MVV),最大通气量(FVC),FEV_(1)/FVC,白细胞介素-6(IL-6),二氧化碳分压(PaCO_(2)),C反应蛋白(CRP),T淋巴细胞亚群(CD8^(+)、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))和肿瘤坏死因子(TNF-α)水平。结果治疗后试验组临床总有效率为97.87%(46/47),高于参照组的82.98%(39/47),差异有统计学意义(P<0.05)。治疗后,试验组MVV、FVC、FEV_(1)/FVC及FEV_(1)水平高于参照组,差异有统计学意义(P<0.05);与参照组比较,试验组PaCO_(2)水平较低,PaO_(2)水平较高,差异有统计学意义(P<0.05);与参照组比较,试验组+CD8水平较低,CD4^(+)、CD4^(+)/CD8^(+)、CD3^(+)水平较高,差异有统计学意义(P<0.05);试验组IL-6、CRP、TNF-α水平均显著低于参照组,差异有统计学意义(P<0.05)。结论匹多莫德联合沙美特罗替卡松治疗对支气管哮喘患儿疗效显著,可增强肺功能,改善血气分析指标,抑制炎症发展,增强免疫力,有助于病情恢复。

全身性糖皮质激素在小儿重症肺炎治疗中的应用价值分析

目的 研究小儿重症肺炎(severe pneumonia, SP)患儿行全身性糖皮质激素治疗的效果。方法 随机选取2019年1月-2021年10月泗洪县第一人民医院收治的120例小儿SP患儿,按随机数表法分为参照组(匹多莫德治疗,n=60)和科研组(地塞米松治疗,n=60),比较分析两组炎症因子、肺功能、血清抗体变化、症状改善及住院时间及临床疗效。结果 用药前两组炎症因子、肺功能及血清抗体比较,差异无统计学意义(P>0.05);用药后与参照组比较,科研组白介素-1、白介素-6、肿瘤坏死因子-α、γ-干扰素指标更低,用力肺活量、第1秒用力呼气容积、第1秒用力呼气容积/用力肺活量、呼气峰值流速指标更高,免疫球蛋白G、免疫球蛋白M、免疫球蛋白A指标更高,体温恢复正常、肺部啰音消失、咳嗽喘息消失及住院时间更短,差异有统计学意义(P<0.05);科研组治疗有效率(96.67%)高于参照组(83.33%),差异有统计学意义(χ^(2)=5.926,P<0.05)。结论 地塞米松治疗小儿SP患儿可降低炎症、改善肺功能,提高免疫球蛋白,增强治疗效果,值得推崇。

通窍鼻炎颗粒结合匹多莫德口服溶液治疗小儿过敏性鼻炎的临床效果

目的探讨通窍鼻炎颗粒结合匹多莫德口服溶液治疗小儿过敏性鼻炎的临床效果。方法选取2021年1月至12月收治的48例过敏性鼻炎患儿作为研究对象,依据入院编号的奇偶性将其分为对照组与观察组,每组24例。对照组给予匹多莫德口服溶液治疗,观察组在对照组治疗基础上给予通窍鼻炎颗粒治疗。比较两组的临床疗效、炎症指标、临床症状评分、呼吸相气流阻力以及药物不良反应发生情况。结果观察组的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的白细胞介素-5(IL-5)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)及呼出气一氧化氮(e NO)水平显著低于对照组,白细胞介素-10(IL-10)水平显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的喷嚏、鼻溢、鼻塞评分及呼气相气流阻力、吸气相气流阻力明显低于对照组,差异具有统计学意义(P<0.05)。两组的药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论通窍鼻炎颗粒结合匹多莫德口服溶液治疗小儿过敏性鼻炎可有效改善临床症状,促进小儿的病情转归,减小疾病对免疫系统造成的压力,具有重要的临床应用价值。

清金化痰益肺汤联合匹多莫德治疗老年支气管肺炎患者的效果

目的:观察清金化痰益肺汤联合匹多莫德治疗老年支气管肺炎患者的效果。方法:回顾性分析2020年12月至2022年12月该院收治的120例老年支气管肺炎患者的临床资料,按照治疗方案不同将其分为对照组和研究组各60例。两组均进行对症治疗,在此基础上,对照组予以匹多莫德治疗,研究组在对照组基础上联合清金化痰益肺汤治疗,两组均治疗2个月。比较两组临床疗效,治疗前后中医证候积分、血清炎性因子[可溶性髓样细胞触发受体-1(sTREM-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、半胱氨酰白三烯(CysLTs)]水平,以及不良反应发生率。结果:研究组治疗总有效率为91.67%(55/60),高于对照组的75.00%(45/60),差异有统计学意义(P<0.05);治疗后,研究组咳痰黄稠、喉间痰鸣、气喘息粗等中医证候积分均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组血清IL-6、TNF-α、CRP、CysLTs、sTREM-1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:清金化痰益肺汤联合匹多莫德治疗老年支气管炎患者可提高治疗总有效率,降低中医证候积分和炎性因子水平,效果优于单纯匹多莫德治疗。